WHO Issues Warning Over Critical Shortage of Obesity Injections
Under a tenth of individuals who could benefit from weight-loss injections such as Wegovy have access to them, states the World Health Organization as it issues its initial advice on the therapies.
Considering over a billion people worldwide currently classified as obese, it is calling for broader and more equitable availability to GLP-1 medication.
Per forecasts, more than two billion could be living with obesity by 2030 if no action is taken.
"Our latest guidance recognises that obesity is a chronic disease that can be addressed with comprehensive and continuous care," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are major obstacles to universal access to the treatments that can aid individuals in losing considerable weight, notes the organization.
Weight-Loss Drug Scarcity
Even in the present best projected scenario, the production of such drugs could only cover approximately 100 million people – under 10% of the global need, according to the WHO.
The recommendation urges governments and firms to widen availability, via measures including patent sharing.
Exclusive production rights on a key compound – the core ingredient of a leading brand – is due to expire in multiple nations in 2026.
How Obesity Injections Operate
The injections imitate a biological compound to reduce digestion speed, reduce hunger and increase satiety so people consume fewer calories.
People commonly begin shedding pounds after several weeks of starting on the weekly injections.
Evidence points to patients may see weight return a year later of halting the drug, because their usual food cravings come back.
To be above a healthy weight elevates your likelihood for contracting health problems, like diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight concerns individuals in every country and was responsible for millions of deaths worldwide in 2024, according to the WHO.
